drugset / Trial / NCT01259193
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC. Zoledronic acid is used for treatment of bone metastasis of diverse malignant cancer. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. The objectives of the study is to evaluate the safety of Sorafenib combined with Zoledronic Acid and to evaluate overall survival and time to progression.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Zoledronic acid | Other / unclassified | 4 mg | — |